Non Alcoholic Steatohepatitis Nash Market Scope And Analysis

Report Code : TIPRE00009653
Category : Pharmaceuticals

No. of Pages : 150

Buy Now

Non-Alcoholic Steatohepatitis (NASH) Market Scope, Growth, Size and Share by 2028

Buy Now

Non-Alcoholic Steatohepatitis Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 3.53 Billion
Market Size by 2031	US$ 77.42 Billion
Global CAGR (2023 - 2031)	47.10%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Product Vitamin E and Pioglitazone Ocaliva Elafibranor Selonsertib & Cenicriviroc By Application Treatment and Diagnosis By Sales Channel Hospital Pharmacy Online Provider Retail Pharmacy
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Genfit SA One Way Liver S L BioPredictive S A S Cadila Pharmaceuticals Ltd Prometheus Laboratories Siemens Healthineers AG Intercept Pharmaceuticals Inc Novartis AG Galmed Pharmaceuticals Laboratory Corporation of America Holdings

Non-Alcoholic Steatohepatitis Market News and Recent Developments

The non-alcoholic steatohepatitis market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the non-alcoholic steatohepatitis market are listed below:

Novartis announced that it had signed an agreement with Carisma Therapeutic to manufacture the HER 2 targeted CAR-M cell therapy, tested in initial trials to treat solid tumors. (Source: Novartis AG, Press Release, March 2022)
Siemens Healthineers announced the launch of the Enhanced Liver Fibrosis (ELF) Test in US. This is the first time the test is commercially available in the U.S., following De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) in August 2021. (Source: Siemens Healthineers AG, Press Release, January 2022)

Non-Alcoholic Steatohepatitis Market Report Coverage and Deliverables

The “Non-Alcoholic Steatohepatitis Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Non-alcoholic steatohepatitis market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Non-alcoholic steatohepatitis market trends as well as market dynamics such as drivers, restraints, and key opportunities
Detailed PEST/Porter’s Five Forces and SWOT analysis
Non-alcoholic steatohepatitis market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments.
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the non-alcoholic steatohepatitis market
Detailed company profiles